Top-News
Dienstag,
18.10.2016 14:35
von
PR Newswire
| Aufrufe: 52
StockNewsNow.com Publishes New SNNLive Video Interview with ProMIS Neurosciences, Inc. Providing Company Overview, Milestones for 2016-2017
Ein Arzt berät einen Patienten (Symbolbild).
© TommL / Vetta / Getty Images
https://www.gettyimages.de/
PR Newswire
LOS ANGELES, Oct. 18, 2016
LOS ANGELES, Oct. 18, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Gene Williams, Executive Chairman of ProMIS Neurosciences Inc. (TSX: PMN). The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS, according to the Company's website (see here: www.promisneurosciences.com). The video interview was recorded on Tuesday, September 13th, 2016 during Media Day 2016 at WestPark Capital in New York City, NY.
Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:
You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS
Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.
Company description and for more information about ProMIS Neurosciences, Inc., please visit: www.ProMISNeurosciences.com
About StockNewsNow.com
StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.
Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stocknewsnowcom-publishes-new-snnlive-video-interview-with-promis-neurosciences-inc-providing-company-overview-milestones-for-2016-2017-300346491.html
SOURCE StockNewsNow.com
Werbung
Mehr Nachrichten zur ProMIS Neurosciences Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
